Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 1100
- Registration Number
- NCT04985266
- Locations
- 🇬🇧
Barnet Hospital, London, Barnet, United Kingdom
🇬🇧Royal Sussex Hospital, Brighton, United Kingdom
🇬🇧Velindre Cancer Centre, Cardiff, United Kingdom
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 866
- Registration Number
- NCT04975308
- Locations
- 🇺🇸
USO - Texas Oncology - Allen, Allen, Texas, United States
🇦🇺Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia
🇺🇸Ironwood Cancer & Research Centers, Chandler, Arizona, United States
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04869943
- Locations
- 🇺🇸
Banner Health/ Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Texas Oncology Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of Miami- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04852081
- Locations
- 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- First Hospital of China Medical University
- Target Recruit Count
- 1354
- Registration Number
- NCT04666805
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 43
- Registration Number
- NCT04659551
- Locations
- 🇮🇹
Arcispedale S. Anna, Cona, FE, Italy
🇮🇹Azienda Ospedaliera Universitaria di Parma, Parma, PR, Italy
🇮🇹Arcispedale S. Maria Nuova, Reggio Emilia, RE, Italy
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT04572295
- Locations
- 🇯🇵
Eisai Trial Site 10, Kitaadachi-gun, Saitama, Japan
🇯🇵Eisai Trial Site 2, Shinagawa-ku, Tokyo, Japan
🇯🇵Eisai Trial Site 6, Kashiwa, Chiba, Japan
Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2023-10-17
- Target Recruit Count
- 30
- Registration Number
- NCT04465097
- Locations
- 🇨🇳
The first affiliated hospital of Sun Yat-Sen university, Guangzhou, Guangdong, China
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Ente Ospedaliero Ospedali Galliera
- Target Recruit Count
- 23
- Registration Number
- NCT04460807
- Locations
- 🇮🇹
ASST degli Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹Azienda Ospedaliera per l'emergenza Cannizzaro, Catania, CT, Italy
🇮🇹UOS Oncologia Ginecologica, Ospedale S. Gerardo, Monza, MB, Italy
Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Instituto Jalisciense de Cancerologia
- Target Recruit Count
- 300
- Registration Number
- NCT04389424
- Locations
- 🇲🇽
Instituto Jalisciense de Cancerologia, Guadalajara, Jalisco, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.